Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19

Basit Öğe Kaydı
dc.authorid0000-0002-9815-1848
dc.contributor.authorAltay, Özlem
dc.contributor.authorArif, Muhammad
dc.contributor.authorLi, Xiangyu
dc.contributor.authorYang, Hong
dc.contributor.authorAydın, Mehtap
dc.contributor.authorAlkurt, Gizem
dc.contributor.authorKim, Woonghee
dc.contributor.authorAkyol, Doğukan
dc.contributor.authorZhang, Cheng
dc.contributor.authorDinler Doğanay, Gizem
dc.contributor.authorTürkez, Hasan
dc.contributor.authorShoaie, Saeed
dc.contributor.authorNielsen, Jens
dc.contributor.authorBoren, Jan
dc.contributor.authorOlmuşçelik, Oktay
dc.contributor.authorDoğanay, Levent
dc.contributor.authorUhlen, Mathias
dc.contributor.authorMardinoğlu, Adil
dc.date.accessioned2021-10-11T08:53:26Z
dc.date.available2021-10-11T08:53:26Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractCOVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD(+)) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID-19 patients. CMAs include l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form of l-carnitine. Placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials are conducted to investigate the time of symptom-free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
dc.description.sponsorshipScandiBio Therapeutics ; Knut & Alice Wallenberg Foundation ; PoLiMeR Innovative Training Network (Marie Skodowska-Curie Grant) from the European Union's Horizon 2020 research and innovation programmeen_US
dc.identifier.citationAltay, Ö., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G. ... Mardinoğlu, A. (2021). Combined metabolic activators accelerates recovery in mild-to-moderate COVID-19. Advanced Science, 8(17). https://dx.doi.org/10.1002/advs.202101222
dc.identifier.doi10.1002/advs.202101222
dc.identifier.issn2198-3844
dc.identifier.issue17
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://dx.doi.org/10.1002/advs.202101222
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8412
dc.identifier.volume8
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofAdvanced Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectCombined Metabolic Activators
dc.subjectCOVID-19
dc.subjectMetabolomics
dc.subjectOmics Data
dc.subjectProteomics
dc.titleCombined metabolic activators accelerates recovery in mild-to-moderate COVID-19
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Olmuscelik-Oktay-2021.pdf
Boyut:
5.25 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu